EUTHYMICS – ANSWERS FOR NEXT-GENERATION ANTIDEPRESSANTS

Euthymics Bioscience’s core focus is to address unmet needs for patients with major depression who do not respond adequately to current medications. We have a highly experienced team of researchers with a track record of success, and a science platform that provides a unique approach to CNS disorders.

LEAD PROGRAM: UNBALANCED TRIPLE REUPTAKE INHIBITOR for MAJOR DEPRESSION

Our lead product candidate, EB-1010, is a novel, BROAD-SPECTRUM MONOTHERAPY antidepressant. Our goal is to improve efficacy while reducing side effects that can compromise compliance.

By individually “tuning” the affinity for three neurotransmitters – serotonin, norepinephrine and dopamine – this triple reuptake inhibitor has demonstrated proof-of-concept efficacy as monotherapy for major depression without causing weight gain or the loss of sexual function, and without the complexities of add-on medications.

A major US phase II/III trial of EB-1010 is planned to start in the first half of 2011.